Thymosin Beta 4 Sequence: The Complete 43-Amino Acid Chain

Thymosin beta 4 is a naturally occurring 43-amino acid peptide whose complete sequence is Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES. Researchers read the thymosin beta 4 sequence in either one-letter or three-letter code, and the order of those residues determines how the peptide binds actin, helps cells migrate, and behaves in laboratory assays.

The Full Thymosin Beta 4 Sequence, Residue by Residue

Thymosin beta 4 is encoded by the TMSB4X gene on the X chromosome. The gene product is a 44-residue precursor; once the initiator methionine is removed and the new N-terminus is acetylated, the mature peptide is 43 residues long and weighs roughly 4.9 kDa.

In three-letter notation, the mature chain reads:

Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser

The same chain in one-letter notation is Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES. At 43 residues it is often called the thymosin beta 4 protein, but by size it is a peptide rather than a protein.

Key Regions Inside the Sequence

Two short stretches inside the chain carry most of the biological activity that researchers study.

Region	Residues	Sequence	Role in research
N-terminal tetrapeptide	1-4	Ac-SDKP	Cleaved off by prolyl oligopeptidase; studied separately in fibrosis and cardiac models
Central linker	5-16	DMAEIEKFDKSK	Adds charge and solubility; contains the chain's only phenylalanine
Actin-binding motif	17-23	LKKTETQ	Primary site for G-actin binding and sequestration
C-terminal tail	24-43	EKNPLPSKETIEQEKQAGES	Highly charged; contributes to peptide stability in solution

The Ac-SDKP Fragment at the N-Terminus

Prolyl oligopeptidase trims the first four residues from thymosin beta 4 and releases Ac-SDKP, a tetrapeptide with its own research literature. Ac-SDKP is studied as a regulator of collagen deposition and blood vessel formation, and it is often measured as a downstream marker when scientists track thymosin beta 4 activity.

The Actin-Binding Motif at Residues 17-23

The stretch LKKTETQ, with the shorter core LKKTET inside it, is the part of the chain that grabs G-actin. Synthetic versions of thymosin beta 4 fragment 17-23 are used in cell-migration experiments because the short piece keeps much of the parent molecule's actin-binding behavior at a fraction of the size.

Why There Are No Cysteine Residues

The chain contains no cysteine, tyrosine, or tryptophan. With no cysteines available, the peptide cannot form disulfide bridges, so it stays linear and largely unstructured in buffer. The absence of cysteines is one reason solid-phase synthesis of the full 43-mer is routine and relatively inexpensive.

Sequence vs. Structure of the Thymosin Beta 4 Protein

A sequence is a string of letters. A structure is what the chain actually does in water, and thymosin beta 4 stays mostly unfolded until it finds a binding partner.

In cells, the peptide binds monomeric G-actin through the LKKTET region and keeps a pool of actin available for polymerization. Roughly one in ten actin monomers in a typical cell is bound to thymosin beta 4, which is why the molecule is described as an actin-sequestering peptide rather than a signaling hormone.

Detecting the Sequence in the Lab: ELISA and Antibody Tools

Because the peptide is short, conserved across mammals, and chemically simple, it is easy to generate reagents against it. Most commercial kits raise a thymosin beta 4 antibody against either the acetylated N-terminus or the central region of the chain, and the choice of epitope determines whether the assay sees full-length peptide or a cleavage fragment.

Quantitative work usually runs on a thymosin beta 4 ELISA, a sandwich assay that captures the peptide with one antibody and detects it with a second. Sample handling matters, because thymosin beta 4 is abundant inside cells and hemolyzed or lysed samples will read artificially high.

What the Sequence Means for Real-World Use

Thymosin beta 4 is not FDA-approved for any human indication in the United States. It also appears on the World Anti-Doping Agency prohibited list under class S2, peptide hormones and growth factors, so tested athletes cannot use it.

Most human interest comes from tissue-repair, eye-surface, and cardiac research. Human evidence for thymosin beta 4 remains mostly preclinical or early-phase, which is why the most-cited thymosin beta 4 benefits are still experimental rather than established. A thymosin beta 4 injection is not available through US pharmacies, and dosing information circulating online is not backed by approved labeling.

People who stack recovery peptides frequently search for bpc-157 and thymosin beta 4 dosage at the same time, but no controlled trial has tested that combination in humans. Because the molecule is sold for laboratory use, most thymosin beta 4 reviews come from self-experimenters rather than clinical data, and self-reported results should be read with that in mind.

Quick Sequence Facts

• Length: 43 amino acids after removal of the initiator methionine.
• N-terminus: acetylated, which slows degradation by cellular peptidases.
• Molecular weight: approximately 4.9 kDa.
• Gene: TMSB4X on the X chromosome, with a related copy, TMSB4Y, on the Y chromosome.
• Notable motif: LKKTETQ at residues 17-23, the actin-binding site.
• Status: not FDA-approved for human use and banned in competitive sport.

Anyone considering peptide use for a health goal should talk with a licensed healthcare professional first, since research-grade material is not manufactured or tested to medication standards.

COMMON QUESTIONS

Frequently Asked Questions

What is the amino acid sequence of thymosin beta 4?

The mature sequence is Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES, a 43-residue chain with an acetylated N-terminus. In three-letter code it reads Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser.

Is thymosin beta 4 the same as TB-500?

No. Thymosin beta 4 is the full 43-amino acid peptide, while TB-500 is a synthetic peptide modeled on its actin-binding region, roughly residues 17-23. That shorter fragment keeps actin-binding activity but is not identical to the parent molecule found in the body.

Is thymosin beta 4 FDA-approved for human use?

No. Thymosin beta 4 is not FDA-approved for any human indication in the United States, and it is prohibited by WADA for competitive athletes. Products sold online are research chemicals rather than approved medications, and they have not been evaluated for human safety or purity.